

Ciplox-250/500

Ciprofloxacin 250 mg / 500 mg Tablets

Cipla

The Cost Effective Antibacterial


The Most Active Antibacterial

| Species | Ciplox-250/500 | Gentamicin | Ampicillin | Cefotaxime | Carbenicillin | Cefoperazone |
|---------------------------|----------------|------------|------------|------------|---------------|--------------|
| <i>E. coli</i> | 0.015 | 3.1 | >100.0 | 0.2 | 4.0 | 1 |
| <i>Klebsiella</i> | 0.03 | 1.6 | 100.0 | 0.4 | >64.0 | 2 |
| <i>Pseudomonas</i> | 0.5 | 2-128.0 | >100.0 | 64.0 | >400.0 | 16 |
| <i>Proteus Sp.</i> | 0.03 | 3.2 | 50.0 | 6.0 | 1.0 | 1 |
| <i>S. aureus</i> | 1.0 | 16.0 | 25.0 | 8.0 | | 4 |
| <i>Providencia Sp.</i> | 0.015 | 12.5 | | 1.6 | 1.0 | |
| <i>Enterobacteriaceae</i> | 0.015 | 8.0 | >128.0 | 0.25 | | 8 |
| <i>H. influenzae</i> | 0.008 | 1.0 | >25.0 | 0.04 | | |


The High Success Antibacterial

RESPIRATORY TRACT INFECTIONS

Lower Respiratory Tract Infections




Pulmonary exacerbations of Cystic Fibrosis



“Oral ciprofloxacin (*Ciplox*) has been shown to provide an effective and well tolerated alternative to standard parenteral therapy, generally achieving clinical improvements in over 90% of episodes.”¹

SKIN AND SOFT TISSUE INFECTIONS

Mild to moderate SSTIs



“Oral ciprofloxacin (*Ciplox*) 750 to 1500 mg/day generally achieved clinical cure in over 70% of patients with various infections of skin and soft tissue, mainly cellulitis, abscesses and infected ulcers or wounds of Gram-positive aetiology.”²

COMPLICATED URINARY TRACT INFECTIONS

“Cure rates with oral ciprofloxacin (*Ciplox*) in UTIs complicated with catheterization or urinary tract abnormality have generally exceeded 80%.”³

Ciplox-250/500


Ciprofloxacin 250 mg / 500 mg Tablets

Cipla

The Cost Effective Antibacterial

The High Success Antibacterial

BONE AND JOINT INFECTIONS



“Oral ciprofloxacin (Ciplox) has achieved an overall clinical cure of 78% in patients with osteomyelitis mainly caused by *P. aeruginosa* with or without other pathogens.”⁴

References:
1-4. *Pharmacoeconomics (Focus on Oral Ciprofloxacin)*, 4 May 1993, Vol. 3, No. 5 (pp. 398-421)

DOSAGE GUIDELINES

| Type of Infection | Oral Dosage | Intravenous Dosage | Type of Infection | Oral Dosage | Intravenous Dosage |
|---|--------------------------------------|------------------------|--------------------------------|---------------------------|--------------------|
| Respiratory Tract, Bone and Joint, Skin/Soft tissue | 500-700 mg twice daily | 200 mg twice daily | Gonorrhoea | 250 mg single dose | 100 mg single dose |
| Urinary Tract | 250-500 mg twice daily | 100-200 mg twice daily | Non-gonococcal urethritis | 750 mg twice daily | |
| Infectious Diarrhoea | 250-500 mg twice daily | | Chancroid | 500 mg twice daily | |
| Enteric Fever (Typhoid) | 500-750 mg twice daily for 7-14 days | | Other infections | 500-750 mg twice daily | 200 mg twice daily |
| | | | Patients with renal impairment | Half the recommended dose | |

CIPLA – YOUR HEALTHCARE PARTNER SINCE 1935

Produced by **CIPLA**, a leading provider of generic pharmaceuticals.

Key Facts about CIPLA:

- 25 manufacturing facilities approved by leading regulatory authorities including the FDA (USA), MHRA (U.K.) and TGA (Australia).
- Over 1000 Formulations and 150 Active Pharmaceutical Ingredients.
- Prequalified and Approved by the World Health Organisation (WHO) for supply to UN Agencies.
- The World's largest range of antiasthmatic aerosols and inhalation devices.
- The World's largest manufacturer of antiretroviral drugs and supplier to the Clinton Foundation AIDS/HIV Initiative.

Distributed by
Controlled Medications Ltd
Unit 204, 2/F New Bright Building
11 Sheung Yuet Road, Kowloon Bay
Kowloon, Hong Kong
Tel: (852) 2896 0889
Fax: (852) 2898 9842
www.swedishtrading.com/conmed

conmed
Controlled Medications Ltd.
康德行有限公司